mucin production pathway

The mucin production pathway encompasses the synthesis, enzymatic modification (notably O-glycosylation), packaging, and regulated secretion of high-molecular-weight glycoproteins called mucins by epithelial cells[2][3][5]. Key steps include gene transcription of mucin genes (e.g., MUC1–MUC21), glycosylation in the ER and Golgi, assembly into granules, and exocytosis mediated by SNARE proteins (e.g., VAMP8, SNAP23), scaffolding proteins (e.g., Munc18b), and regulatory factors responsive to calcium and second messengers[1][3][5]. This pathway is essential for maintaining mucus barriers in respiratory, gastrointestinal, and reproductive tracts, providing defense against pathogens, modulating immunity, and maintaining tissue homeostasis. Dysregulation leads to pathological mucus accumulation (as in chronic respiratory or intestinal diseases) or defective barrier function[1][4][5][7]. If the intent is to define a therapeutic target, it is recommended to focus on specific mucin proteins (e.g., MUC5AC, MUC2), enzymes regulating their synthesis, or molecular machinery responsible for exocytosis rather than the synthesis/secretion pathway as a whole[1][5][7].

Other names

mucin biosynthesis pathwaymucin secretion pathwaymucus production pathway

Mucin secretion inhibitors (target SNARE machinery/exocytosis). Mucolytics (act on mature mucus to reduce viscosity). Anti-inflammatory agents (reduce stimulated mucin secretion).